· IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT

: JACKOWSKI et al.

INVENTION:

: BIOPOLYMER MARKER INDICATIVE OF DISEASE STATE HAVING A MOLECULAR **WEIGHT OF 1211 DALTONS**

SERIAL NUMBER

: 09/845,731

FILING DATE

: 04/30/01

RECEIVED

EXAMINER:

: (not assigned yet)

GROUP ART UNIT

: 1645

TECH CENTER 1600/2900

ATTORNEY DOCKET NO.

: 2132.029

TRANSMITTAL LETTER

CERTIFICATE UNDER 37 CFR 1.8(a) deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on 3.49.7

Box Sequence U.S. Patent & Trademark Office P.O. Box 2327 Arlington, VA 22202

Sir:

Please find enclosed for filing:

- Response to Notice to Comply with Requirements
- Supplemental Preliminary Amendment
- Computer Readable Form Sequence Listing (paper copy-1 sheet)
- Computer Readable Form Sequence Listing (diskette).
- Copy of Notice to Comply with Requirements
- Please charge any deficiencies or credit any overpayment to Deposit Account No. 50-1803. This Transmittal Letter is submitted in duplicate.

Date: _ 3-19-2002

Respectfully submitted,

Eines H. Camelow

Ferris H. Lander Registration No. 43,377

McHale & Slavin, P.A.

4440 PGA Boulevard, Suite 402 Palm Beach Gardens, FL 33410

Telephone: (561) 625-6575

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT

: JACKOWSKI et al.

INVENTION:

BIOPOLYMER MARKER INDICATIVE OF DISEASE STATE HAVING A MOLECULAR

WEIGHT OF 1211 DALTONS

SERIAL NUMBER

: 09/845,731

RECEIVED

FILING DATE

: 04/30/01

APR 0 1 2002

EXAMINER:

: (not assigned yet)

TECH CENTER 1600/2900

GROUP ART UNIT

: 1645

ATTORNEY DOCKET NO.

: 2132.029

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS

CERTIFICATE UNDER 37 CFR 1.8(a) I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on 3-19-02

Box Sequence U.S. Patent & Trademark Office P.O. Box 2327 Arlington, VA 22202

Sir:

In the above-identified application, Applicants have received a Notice to Comply with Requirements for Patent Applications mailed February 22, 2002, indicating that the application did not include the sequence list under 37 C.F.R. 1.821-1.825.

Applicants also submit herewith a copy of the Notice To Comply with Requirements for Patent Applications mailed February 22, 2002.

IN THE SPECIFICATION:

Prior to the Claims, please add the following sequence listing:

Applicants have now complied with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures. A separate paper copy and an electronic form of the sequence listing are attached hereto. The information recorded in computer readable form is identical to the written sequence listing, neither of which contain new matter. In response to the Notice to Comply with Requirements dated February 22, 2002, Applicants submit the application complies with the requirements under 37 C.F.R. §1.821-1.825.

Having now complied with all of the outstanding filing requirements, Applicants respectfully request that this application be placed upon the files for examination.

Date: 3-19-2002

Respectfully submitted,

Ferris H. Lander

Registration No. 43,377

McHale & Slavin, P.A.


4440 PGA Boulevard, Suite 402

Palm Beach Gardens, FL 33410

Telephone: (561) 625-6575

E:\FILES\SH\SYN X\syn x-pto-ltrs 4-30\2132.029 resp comply.wpd







United States Patent and Trademark Office

PATENTS DEMANK OFFICE

WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/845,731

04/30/2001

George Jackowski

2132.029

CONFIRMATION NO. 3804

FORMALITIES LETTER

Michael A. Slavin McHale & Slavin, P.A. 4440 PGA Blvd., Suite 402 Palm Beach Gardens, FL 33410



OC000000007521757

Date Mailed: 02/22/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Nτ

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE